Early changes of cTnT and NT-proBNP in neonates underwent ECMO support: a single-center experience

Abstract

Objective: To explore the changes in the absolute value and decline rate of early serum cTnT and NT-proBNP in neonates who underwent V-A ECMO support therapy within one week of birth. Methods: Clinical data and laboratory test results of 17 neonates who underwent V-A ECMO support therapy within one week of birth from January 2020 to January 2023 were retrospectively collected from the electronic medical record system. The patients were divided into the survival group and the death group. The absolute values and decline rate of cTnT and NT-proBNP were compared between the two groups on the day, 24, 48, and 72 hours after ECMO treatment. Result: Of the 17 neonates, 10 survived, and 7 died, with a survival rate of 58.8%. The absolute values of cTnT and NT-proBNP in the survival group were significantly lower than those in the death group, and the decline rate was significantly higher than in the death group. In this study, neonates with no early decline in cTnT and NT-proBNP were all in the death group. Conclusion: The changes in the absolute value and decline rate of early serum cTnT and NT-proBNP in neonates who underwent V-A ECMO may predict their prognosis.